Chronic graft versus host disease (cGVHD) is a significant cause of post-transplant morbidity and mortality. Chronic skin GVHD with associated sclerosis, pigmentation changes, alopecia, restricted joint mobility, and intense pruritus significantly affects quality of life and self-confidence. Topical therapy options for cGVHD of the skin are limited. Topical calcineurin inhibitors, steroid applications, and emollients are often only partially effective, and oily and inconvenient for long-term use. Medications used for pruritus are often sedating and ineffective, so there is significant need for alternative therapies for these patients.
Systemic vitamin D deficiency has been linked to acute and chronic GVHD in multiple studies. We showed that over 70% of stem cell transplant recipients are vitamin D deficient, and severe vitamin D deficiency is associated with inferior survival [1] [2] [3] . The dermatology literature points to inadequate vitamin D receptors (VDR) in the skin in some immune mediated skin disorders [4] . Calcipotriene, a topical vitamin D analog, is thought to increase the number of VDR's in epidermal nuclei. VDR agonists also contribute to control of the innate and adaptive immune system. Topical vitamin D analogs have been used for atopic dermatitis [5] , vitiligo, morphea, and lichen sclerosus et atrophicus owing to its effects on immunoregulation, fibroblast proliferation, collagen synthesis, and endothelial cell function [6] . Vitamin D3 downregulates cellular adhesion molecule expression by inhibiting TNF-α mRNA expression, which has been suggested as a mechanism that alleviates pruritus in patients with steroid refractory prurigo [7] . Calcipotriene was approved by the FDA in 1994 for use in psoriasis only. It has proven to be effective in the treatment of other dermatoses, but there are no reports in the scientific literature using it for the treatment of skin GVHD.
We proposed that topical vitamin D analog application would have a positive effect on chronic skin GVHD due to predominantly cutaneous metabolism. In 2016 we established uniform clinical guidelines to offer topical vitamin D treatment to patients with therapy refractory skin GVHD presenting with intractable pruritus, skin or scalp erythema/desquamation or altered skin pigmentation. Six patients were treated with topical calcipotriene for therapy refractory cGVHD of the skin and/or scalp from June 2016 to January 2017. Patient demographics, disease characteristics, and previous GVHD therapy used is summarized in Table 1 . Chronic GVHD score at the initiation of topical vitamin D therapy was based on the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graftversus-Host Disease: I. The 2014 Diagnosis and Staging Working Group reported by Jagasia et al [8] . Response to therapy was documented by the treating physician using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for each presenting symptom at least weekly. Serial skin and scalp photographs were obtained with caregiver consent. Clinically meaningful and objective response to therapy was counted as symptom reduction by at least one CTCAE grade. Time to response was documented as days from initiation of therapy. Patient and caregiver report about therapy tolerability and compliance were documented, but not scored due to subjectivity. Blood 25-OH vitamin D levels were monitored every 2 weeks in children below 15 kg of weight and those receiving near complete daily body application with calcipotriene. 25-OH vitamin D levels were monitored every 3 months in older children or those receiving partial body applications if levels remained Eyes (1) Mouth (1) Mouth (1) Mouth (1) Eyes (1) Mouth (1) GI tract (2) Joints (1) Eyes (1) GI tract (1) Eyes (1) Lungs (1) Joints (3) Liver (1) Liver (1) Joints (2) Lungs (1) Skin symptom and response to calcipotriene topical therapy within a therapeutic range of 30-60 ng/ml, and monthly or more often if the level was over 60 ng/ml. Three patients had extensive skin cGVHD (overall cGVHD score 3) presenting with dry, flaky and/or erythematous skin with deep sclerotic features involving 80-100% of their body, with changes in pigmentation and refractory pruritus significantly affecting activities of daily life. Two of three patients with overall score 2 skin cGVHD had significant involvement of the scalp presenting as erythematous, flaky, and very pruritic scalp skin with dry brittle hair. One patient with overall skin cGVHD score of 2 had significant desquamation of hands and feet that was very painful and affected daily activities. All but two patients were off systemic therapy due to GVHD unresponsiveness for >30 days prior to initiating topical calcipotriene. One patient was still on extracorporeal photopheresis (ECP) and other on infliximab therapy at the time of calcipotriene initiation. All patients were receiving topical steroids, non-prescription moisturizers, and antipruritic agents without satisfactory response for more than 3 months. Calcipotriene therapy was initiated after receiving a median of 6 months of GVHD targeted therapy (range 3 to 43 months), when patients were deemed nonresponsive to conventional GVHD therapeutic options and continued to have clinical symptoms interfering with activities of daily life. All topical treatments including topical steroid applications were discontinued prior to initiation of topical calcipotriene therapy. All six patients with skin cGVHD were prescribed calcipotriene (DOVO-NEX) 0.005% cream twice a day to affected skin of the body. Patients with scalp skin involvement were also prescribed calcipotriene (SORILUX) foam 0.005% to be applied to their scalp twice a week until erythema and skin desquamation resolved, and then used as needed. Response to topical calcipotriene therapy is listed in Table 1 . The most immediate documented clinical improvement was resolution of intractable pruritus that was noted as early as a couple of days after initiation of topical calcipotriene applications. After 7 days of therapy all patients were pruritus free and did not need any systemic medications for pruritus control (symptom resolution from CTCAE grade 3 to grade 0 by day 7 of therapy). Prompt resolution of pruritus was favorably noted by all care givers stating significant improvement in quality of daily life and cessation for patient requests of systemic antipruritic medications. CTCAE grade 3 skin erythema and dryness resolved in two patients down to CTCAE grade 0 and significantly improved to CTCAE grade 1 in four patients by day 14 of therapy. All three patients with scalp involvement had complete resolution of erythema and skin desquamation by day 7 of therapy using calcipotriene foam (symptom resolution from CTCAE grade 3 to grade 0) (Fig. 1a, b) . Two of four patients with CTCAE grade 3 palm and feet desquamation had complete resolution of symptoms to CTCAE grade 0 by 28 days of therapy. The other two patients had clinically significant improvement in symptoms from CTCAE grade 3 to grade 1 in first 28 days and continued to improve over time on topical calcipotriene therapy. These patients achieved complete symptom resolution after 3 months of therapy without any reported side effects attributed to the drug (Fig. 1c, d) .
None of these patients received any other topical medications nor escalated any systemic therapy during calcipotriene administration time. Five patients tapered calcipotriene cream use from twice a day to as needed schedule at a median of 6 weeks from therapy initiation (range 1-20 weeks). At the time of this report these patients have received 5-8 months of therapy and continue to use calcipotriene skin applications intermittently as needed (ranging from once a week to twice a month) with sustained clinical response and no reported side effects. One patient (patient #1) continues to use nearly full body applications of calcipotriene cream daily for symptomatic relief of extensive skin cGVHD and continues to gain clinical benefit with improved skin texture and pigmentation (Fig. 1e, f) .
Our study indicates that topical vitamin D analog (Calcipotriene) applications could be a promising novel therapeutic option for chronic skin and scalp GVHD, especially for those presenting with intense pruritus not responsive to other targeted anti-GVHD and antipruritic therapies. All six of our patients with therapy refractory skin cGVHD had complete resolution of pruritus within one week of therapy, followed by clinically meaningful improvement of skin dryness and erythema allowing discontinuation of systemic antipruritic and pain medications. More chronic skin changes took a longer time to respond, as might be expected, but continued to improve over time without reported discomfort or side effects attributable to the drug.
Patients and caregivers were most satisfied with the prompt control of pruritus and overall pleasant feeling of the calcipotriene cream and foam. The treatment was well absorbed into the skin without leaving the oily residues associated with many topical therapies, making this therapy well tolerated even in young children who often resist topical medication applications. Patients reported improved compliance with prescribed calcipotriene applications specifically for that particular reason.
We observed some potential systemic vitamin D absorption, especially in our young patient with near complete body applications of the calcipotriene, so routine monitoring of blood vitamin D 25-OH levels should be performed for patients receiving topical calcipotriene therapy [9, 10] .
We were not equipped in this study to objectively evaluate the effect of calcipotriene on sclerotic GVHD changes, as this would require objective skin thickness measurements, but we are planning to examine this in future prospective studies. Our current observations in this small cohort of patients provide valuable data for future study planning to investigate topical vitamin D analog use and its effect on cGVHD and to better understand the role of vitamin D in cGVHD pathogenesis.
